Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
1
users have commented on this narrative
39
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Newron Pharmaceuticals
HE
HedgeY
Community Contributor
Newron Pharmaceuticals (NWRN) – Binary CNS Bets with 3-to-1 Upside
1. Catalysts Evenamide (Schizophrenia Add-On Therapy): The key growth catalyst for Newron is Evenamide, a novel glutamate-modulating drug in Phase III development for treatment-resistant schizophrenia (TRS).
View narrative
CHF 17.00
FV
55.6% undervalued
intrinsic discount
32.43%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
about 1 month ago
author updated this narrative
West Red Lake Gold Mines
AG
Agricola
Community Contributor
A case for CAD$ 11.28 (USD $8.30) by 2029
Below is an analysis of West Red Lake Gold Mines Ltd. (TSXV: WRLG) assuming a successful restart of the Madsen mine and Rowan property, a precious metals bull market, and specific economic conditions.
View narrative
CA$11.28
FV
92.2% undervalued
intrinsic discount
0%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
2
users have commented on this narrative
2
users have followed this narrative
about 2 months ago
author updated this narrative
Advanced Micro Devices
ZW
Zwfis
Community Contributor
AMD's Future Looks Promising with a 31% Revenue Growth
Price: $138.52 (7/2/25) Willing To Pay: <= $195 As of right now I am incredibly bullish; AMD is actually my largest position in my portfolio right now so take that into consideration. Now when you look at AMD in value not considering its growth potential you would probably find its value to land between $130-$100 with its intrinsic value roughly coming to $101.87.
View narrative
US$290.64
FV
37.7% undervalued
intrinsic discount
31.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
1
users have commented on this narrative
27
users have followed this narrative
about 1 month ago
author updated this narrative
iShares Trust - iShares U.S. Aerospace & Defense ETF
NO
North49_
Community Contributor
Anticipating Steady Growth for iShares U.S. Aerospace & Defense ETF
The investment seeks to track the investment results of the Dow Jones U.S. Select Aerospace & Defense Index composed of U.S. equities in the aerospace and defense sector. The index measures the performance of the aerospace and defense sector of the U.S. equity market, as defined by SPDJI.
View narrative
US$248.79
FV
21.2% undervalued
intrinsic discount
0%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
12 days ago
author updated this narrative
Argan
KE
Kerry
Community Contributor
Argan's Revenue Set to Soar with a 13.31% Growth in the Coming Decade
RECENT PAST AGX has consistently delivered robust revenue growth, with fiscal year 2025 revenue rising 53% year-over-year to $874.2 million and net income surging 164% to $85.5 million. In recent quarters, revenue growth has exceeded 60% year-over-year, particularly fueled by performance in its Power Services segment.
View narrative
US$284.68
FV
21.1% undervalued
intrinsic discount
13.31%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
3
users have commented on this narrative
24
users have followed this narrative
2 months ago
author updated this narrative
Whitecap Resources
ST
StjepanK
Equity Analyst and Writer
WhiteCap Is Positioned To Profit Regardless Of Trump's Policy
Key Takeaways I believe the Canadian oil and gas sector is overlooked, mainly because of Donald Trump's upcoming second term. Regardless of Trump tariff risk, which I deem overblown due to economic recoil to the American Midwest, I believe Canadians have hedged their risk, improving exporting infrastructure.
View narrative
CA$22.60
FV
55.0% undervalued
intrinsic discount
3.51%
Revenue growth p.a.
Set Fair Value
26
users have liked this narrative
8
users have commented on this narrative
117
users have followed this narrative
3 months ago
author updated this narrative
Pro Medicus
RO
Robbo
Community Contributor
Great Company.... but so expensive!
Pro Medicus (ASX: PME) is an Australian company that develops medical imaging software under its Visage product range. Leading medical institutions including NYU Langone, UCSF, and Mass General Brigham have publicly or semi-publicly praised the platform—often via PME-issued press releases or interviews.
View narrative
AU$133.68
FV
134.5% overvalued
intrinsic discount
-9.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
about 1 month ago
author updated this narrative
Advanced Micro Devices
CO
codepoet
Community Contributor
A formidable player in AI and enterprise computing.
1. Growth Engines in AI & Data Center AMD reported 36% YoY revenue growth in Q1 2025 , reaching $7.44B , with non‑GAAP EPS of $0.96 , a 55% YoY jump.
View narrative
US$155.00
FV
16.7% overvalued
intrinsic discount
8.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
9 days ago
author updated this narrative
Silo Pharma
CM
CMCVentures
Community Contributor
Groundbreaking therapies that could change the treatment landscape for PTSD, fibromyalgia, MS & Alzheimer’s
Key Takeaways Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple sclerosis (MS). The company’s unique approach of combining traditional drugs with psychedelic-inspired therapies positions it to address significant gaps in the treatment landscape.
View narrative
US$6.20
FV
88.8% undervalued
intrinsic discount
234.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
6
users have commented on this narrative
95
users have followed this narrative
2 months ago
author updated this narrative
Value any company in seconds
Popular companies